Jiaci

Giménez Arnau AM, et al.

J Investig Allergol Clin Immunol 2019; Vol. 29(5): 338-348

doi: 10.18176/jiaci.0323

26. Valero A, Ferrer M, Giménez-Arnau AM, Jauregui I, Ballesteros

C. Utilidad clínica de la versión española de los cuestionarios

Urticaria Activity Score y Urticaria Activity Score-7 para evaluar

la urticaria crónica espontánea. 44th Congreso Nacional de

Dermatología y Venereología (AEDV), 2016 Jun 1-4; Zaragoza,

Spain.

27. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause

K, et al. Development, validation, and initial results of the

Angioedema Activity Score. Allergy. 2013;68:1185-92.

28. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L,

Compalati E, et al. A new tool to evaluate the impact of

chronic urticaria on QoL: chronic urticaria QoL questionnaire

(CU-QoL). Allergy. 2005;60:1073-8.

29. Lennox RD, Leahy MJ. Validation of the Dermatology Life

Quality Index as an outcome measure for urticaria-related

QoL. Ann Allergy Asthma Immunol. 2004;93:142-6.

30. Stull D, McBride D, Houghton K, Georgiou P, Zuberbier

T, Grattan C, et al. Measuring Patient Severity in Chronic

Spontaneous/ Idiopathic Urticaria (CSU/CIU) as Categorical

Health States: Efficient and Informative? European Academy

of Allergy and Clinical Immunology (EAACI) Congress. 2014

Jun 7-11; Copenhagen, Denmark.

31. Khalil S, McBride D, Gimenez-Arnau AM, Grattan C, Balp

MM, Stull D. Weekly Urticaria Activity Score (UAS7) and

Dermatology Life Quality Index (DLQI) in Validation of Chronic

Spontaneous/Idiopathic Urticaria (CSU/CIU) Health States. J

Allergy Clin Immunol. 2015;135 Suppl 2:AB131.

32. Stull D, McBride D, Tian H, Giménez Arnau A, Maurer M,

Marsland A, et al. Analysis of Disease Activity Categories in

Chronic Spontaneous/Idiopathic Urticaria. Br J Dermatol.

2017;177:1093-101.

33. Giménez-Arnau AM,Toubi E, Marsland AM, Maurer M. Clinical

management of urticaria using omalizumab: the first licensed

biological therapy available for chronic spontaneous urticaria.

J Eur Acad Dermatol Venereol. 2016;30 Suppl 5:25-32.

34. Silvestre JF, Giménez-Arnau AM, García-González F, González-

Pérez R, Labrador M, García-Bravo B, et al. Prevalencia de

urticaria crónica refractaria a la terapia estándar en práctica

clínica habitual. 44th Congreso Nacional de Dermatología y

Venereología (AEDV); 2016 Jun 1-4; Zaragoza, Spain.

35. Deza G, García-Colmenero L, Curto-Barredo L, Pujol RM,

Giménez-Arnau AM. Management of Chronic Spontaneous

Urticaria Exacerbated by Antihistamines: Treatment as a

Causal Agent. Acta Derm Venereol. 2016;96:838-9.

36. Tedeschi A. Paradoxical exacerbation of chronic urticaria by

H1-antihistamines and montelukast. Eur Ann Allergy Clin

Immunol. 2009;41:187-9.

37. Giménez-Arnau A, Izquierdo I, Maurer M. The use of a

responder analysis to identify clinically meaningful differences

in chronic urticaria patients following placebo- controlled

treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol

Venereol. 2009;23:1088-91.

38. Sánchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of

Antihistamines in Chronic Spontaneous Urticaria Based on

Initial Suppression of the Histamine-Induced Wheal. J Investig

Allergol Clin Immunol. 2016;26:177-84.

39. Joshi S, Khan DA. The Expanding Field of Biologics in the

Management of Chronic Urticaria. J Allergy Clin Immunol

Pract. 2017;5:1.489-99.

40. Casale TB, Bernstein JA, Maurer M, Saini SS,Trzaskoma B, Chen

H, et al. Similar Efficacy with Omalizumab in Chronic Idiopathic/

Spontaneous Urticaria Despite Different Background Therapy.

J Allergy Clin Immunol Pract. 2015;3:743-50.e1.

41. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Fleich

GJ, et al. The effect of omalizumab dosing and frequency in

chronic idiopathic urticaria: Retrospective chart review. J Am

Acad Dermatol. 2016;74:1274-6.

42. Giménez-Arnau A, Velasco M, Armario Hita JC, Labrador-

Horrillo M, Silvestre-Salvador JF. Omalizumab: what benefits

should we expect? Eur J Dermatol. 2016;26:340-4.

43. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety

of omalizumab in chronic spontaneous or inducible urticaria:

evaluation of 154 patients. Br J Dermatol. 2016;175:404-6.

44. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma

B, Raimundo K, et al. Timing and duration of omalizumab

response in patients with chronic idiopathic/ spontaneous

urticaria. J Allergy Clin Immunol. 2016;137:474-81.

45. Ferrer M, Boccon-Gibod I, Gonçalo M,

nalöz HS, Knulst

A, Lapeere H, et al. Expert opinion: defining response to

omalizumab in patients with chronic spontaneous urticaria.

Eur J Dermatol. 2017;27:455-63.

46. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem

D, et al. Clinical and laboratory parameters in predicting

chronic urticaria duration: a prospective study of 139 patients.

Allergy. 2004;59:869-73.

47. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A,

Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic

spontaneous urticaria. A GA²LEN task force report. Allergy.

2011;66:317-30.

48. Asero R, Marzano AV, Ferrucci S, Cugno M. D-Dimer Plasma

Levels Parallel the Clinical Response to Omalizumab in

Patients with Severe Chronic Spontaneous Urticaria. Int Arch

Allergy Immunol. 2017;172:40-4.

49. Deza G, Bertolín-Colilla M, Pujol RM, Curto-Barredo L, Soto

D, García M, et al. Basophil Fc

RI Expression in Chronic

Spontaneous Urticaria: A Potential Immunological Predictor

of Response to Omalizumab Therapy. Acta Derm Venereol.

2017;97:698-704.

50. Deza G, Bertolín-Colilla M, Sánchez S, Soto D, Pujol RM,

Gimeno R, et al. Basophil Fc

RI expression is linked to time

to omalizumab response in chronic spontaneous urticaria. J

Allergy Clin Immunol. 2018;141:2313-6.e1.

51. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov

PS, et al. Serum autoreactivity predicts time to response to

omalizumab therapy in chronic spontaneous urticaria. J

Allergy Clin Immunol. 2017;139:1059-61.e1.

52. Ferrer M, Giménez-Arnau A, Saldana D, Janssens N, Balp

MM, Khalil S, Risson V. Predicting Chronic Spontaneous

Urticaria Symptom Return After Omalizumab Treatment

Discontinuation: Exploratory Analysis. J Allergy Clin Immunol

Pract. 2018;6:1191-7.e5.

53. Fiorino I, Loconte F, Rucco AS, Nico A, Vacca M, Damiani E, et

al. Long-term treatment of refractory severe chronic urticaria

by omalizumab: analysis of two cases. Postepy Dermatol

Alergol. 2014;31:332-4.

54. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is

an effective and rapidly acting therapy in difficult-to-treat

347